

IgG₁ MM. IgG₃ and IgG₁ have a propensity to form Ig complexes linked together by specific aggregating sites located in the Fd fragments of the immunoglobulin molecules.⁶

Cryoglobulins are proteins that precipitate or gel on cooling and dissolve when heated. Five percent of M-proteins are cryoglobulins.⁷ However, the exact percentage of cryoglobulins in IgG₁ M-protein is not known. The presence of cryoglobulins causes purpura, cold urticaria, leg ulcers, gangrene of the toes, and symptoms of cold intolerance manifested by Raynaud's phenomenon.

The M-protein in this case was of IgG₁ kappa type. It formed a translucent gel at 4°C (Figure 1). The process of gelification was concentration- and temperature-dependent and was reversed by vortexing. The M-protein is not a typical cryoglobulin because it does not form a whitish precipitate that redissolves at 37°C. In fact, specific quantification of cryoglobulins revealed no significant levels even though three-fourths of the monoclonal protein was cryogelified. This was because the abnormal protein was completely redissolved during the washing process and discarded with the washing fluid.

As documented here, the process of reversible gelification can also erroneously lower the apparent paraprotein level and the corresponding serum viscosity if measured only from the top layers of the sample without

previous vortexing (Figures 2 and 3). Clinically, it can cause misdiagnosis, inappropriate downstaging of the disease, or premature withdrawal of chemotherapy.

The mechanism of M-protein gelification-aggregation is unknown. Due to structural polymorphism, monoclonal immunoglobulins easily interact with one other. The reversible self-association may be explained by weak protein-to-protein binding. Aggregation probably involves a combination of dispersion forces,^{8,9} hydrogen binding,¹⁰ and hydrophobic interactions.¹⁰ The dominant factors are unknown.

Similar phenomena have been noted in three other patients with IgM paraproteinemia at this institution. At present we have no clinical evidence that this unusual phenomenon could occur in vivo. The prevalence of the phenomenon is unknown. We feel that it is uncommon but, because of its significant clinical impact in the management of MM, every laboratory should look routinely for this phenomenon. We strongly recommend vortexing of all serum samples just prior to performing the relevant protein studies.

ACKNOWLEDGMENT

We acknowledge the technical assistance of Eva Madszar.

REFERENCES

- Alexanian R. Diagnosis and management of multiple myeloma. [In] Wiernik PH, Canellas GP, Kyle RA, Schiffer CA, eds. *Neoplastic Diseases of the Blood*. New York, Churchill Livingstone, 1985; pp 529–552.
- Bruckman R. Tumor marker in clinical practice. *Br J Hosp Med* 1982; 10:9–14.
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer* 1975; 36:842–854.
- Woodruff RK, Wadsworth J, Malpas JS, Tobias JS. Clinical staging in multiple myeloma. *Br J Haematol*, 1979; 42:199–205.
- Grey HM, Kunkel HG. H chain subgroups of myeloma proteins and normal 7s-kappa-globulin. *J Exp Med* 1964; 120:253–266.
- Capra JD, Kunkel HG. Aggregation of gamma-G₃ proteins: relevance to the hyperviscosity syndrome. *J Clin Invest* 1970; 49:610–621.
- Kyle RA. Multiple myeloma: review of 869 cases. *Mayo Clin Proc* 1975; 50:29–40.
- Middaugh CR, Litman GW. Effect of D₂O on the temperature-dependent solubility of cryoglobulin and noncryoglobulin IgM. *FEBS Lett* 1977; 79:200–202.
- Middaugh CR, Litman GW. Effect of solutes on the cold-induced insolubility of monoclonal cryoimmunoglobulins. *J Biol Chem*, 1977; 252:8002–8006.
- Erikson BW, Gerber-Jenson, B, Wang AC, Litman GW. Molecular basis for the temperature-dependent insolubility of cryoglobulins—XI. Sequence comparison of the heavy-chain variable regions of the human cryoimmunoglobulins McE and Hil by metric analysis. *Mol. Immunol*, 1982; 19:357–365.

Commentary

This article describes a laboratory phenomenon that can have significant clinical consequences. The authors report a case of a patient with multiple myeloma who has a gelifying IgG₁-kappa paraprotein. This gelification process was temperature- and concentration-dependent, and was reversed by vortexing.

The phenomenon of M-protein gelification has been observed in three other patients, and its mechanism is

not understood. Although this phenomenon is uncommon, it can erroneously lower the measured paraprotein level and affect the serum viscosity. Thus it can affect the diagnosis and treatment of certain patients with multiple myeloma.

ANNA KOO, MD
Department of Rheumatology and Immunologic Disease